Study population
All 129 retrospectively included patients underwent clinically indicated prospective ECG-triggered CCTA (Discovery NM 570c, GE Healthcare). The first 45 patients were consecutively included to derive a patient-tailored dose protocol (further referred to as group A). For the validation part of this study, 84 additional patients were included (further referred to as group B), of which 43 patients were included consecutively. To obtain a population in the full expected range of body mass per body length (MPL) to demonstrate the validity of the protocol an additional 41 patients were included to obtain at least 10 patients in each of the following MPL categories: <40, 40–45, 46–50, 51–55 and >55 kg/m. These patients were consecutively included for each category. Multiple patient-specific parameters and coronary artery disease risk factors were collected for all patients prior to scanning. As this study was set up in a retrospective manner, no approval by the medical ethics committee was required. All patients provided written informed consent for the use of their data for research purposes.
Patient preparation and image acquisition
Patients were instructed to remain fasting for 3 h prior to acquisition. Patients with heart rates between 49 and 59 or >59 beats per minute were requested to take 50 or 100 mg metoprolol orally, respectively, 1 h prior to acquisition. Diazepam (10 mg) was administered when clinically indicated to calm the patients for additional heart rate reduction.
Patients were scanned in supine position, with arms placed above their head. A scout image (120 kV, 10 mA) was acquired prior to the bolus acquisition to determine the scan field. Bolus delay was determined by making 10 consecutive acquisitions in 20 s (120 kV, 60 mA). Next, patients were administered two puffs (2 × 0.4 mg) of nitroglycerine sublingual, unless contraindicated.
All CT-scans were prospectively ECG-triggered at 75 % of the RR interval and were acquired using the following parameters: collimation 64 × 0.625 mm, rotation time of 0.35 s and a tube voltage depending contrast flow of 4 ml/s at 100 kV, 5 ml/s at 120 kV, and 6 ml/s at 140 kV (Optiraytm, Mallinckrodt). The standard applied BMI depending protocol in our institution, as applied in group A, is shown in Table 1. The CT scans were reconstructed using filtered back projection with a slice thickness of 0.625 mm, 512 × 512 matrix and a pixel size of 0.35 mm (Xeleris software, GE Healthcare).
Table 1 The applied BMI depending dose protocol for patients in group A including tube settings and estimated radiation dose
Deriving a patient-specific CCTA protocol
The image noise, defined as the standard deviation of pixel attenuation values in a visually homogeneous region of interest (ROI), was measured in the most cranial part of the liver parenchyma in each scan, as illustrated in Fig. 1. Next, image noise was fitted to multiple patient-specific parameters (P) which were considered easy applicable in daily use; body weight, BMI and MPL, to determine a possible increase in image noise for heavier patients (see Table 1).
To determine the relation between image noise and patients’ size for a fixed radiation dose, the measured image noise was normalized to the squared root of the applied computed tomography dose index (CTDI) expressed in mGy. This was based on the formula previously used by Menke et al. [15]:
$${\text{CTDI}} \cdot \upsigma^{2} \propto {\text{e}}^{{\upmu \cdot {\text{d}}}}$$
(1)
Here σ is the measured image noise, µ the mean attenuation coefficient of the region at a defined tube voltage (cm−1) and d the axial diameter of the patient (cm). Subsequently, for each patient a normalized value of image noise (σnorm) was determined using:
$$\upsigma_{\text{norm}} = \upsigma \cdot \surd {\text{CTDI}}$$
(2)
Next, the relations between the σnorm and multiple patient-specific parameters (P) were investigated to find the parameter best explaining the relation between σ and P. Therefore, σnorm was fitted using a linear function (σfit):
$$\upsigma_{\text{fit}} = {\text{a}} \cdot {\text{P}} + {\text{b}}$$
(3)
Here, a and b are fit parameters.
Patient-specific CTDI
When combining Eqs. 2 and 3, with σnorm described by the linear function σfit, we obtained a new CTDI (CTDIapply):
$${\text{CTDI}}_{\text{apply}} = \left( {\frac{{\upsigma_{\text{fit}} }}{{\upsigma_{\text{C}} }}} \right)^{2} = \left( {\frac{{{\text{a}} \cdot {\text{P}} + {\text{b}}}}{{\upsigma_{\text{C}} }}} \right)^{2}$$
(4)
Here σC is the desired constant image noise, which was set equal to the average image noise measured in all patient scans in this study. Ideally, the noise becomes independent of the patient examined when applying the new CTDI using the appropriate tube settings (kV and mA). The choice of tube voltages was based on tube voltage guidelines using weight and BMI; 100 kV below 90 kg or 30 kg/m2 corresponding to a MPL of 45 kg/m, 140 kV for severely obese patients (MPL > 60 kg/m) and 120 kV for the remainder of the patients [4]. Next, the tube currents were derived using these tube voltages to obtain CTDIapply. Yet due to the maximum tube current achievable on the CT scanner, a higher tube voltage of 120 kV was used for MPLs between 45 and 52.5 kg/m to obtain CTDIapply.
To ensure validity of the protocol, it was derived for patients with a body weight between 60 and 130 kg, BMI between 17 and 35 kg/m2 or MPL between 35 and 60 kg/m. Patients outside this pre-specified range received the minimal or maximal recommended radiation dose, i.e. a patient with a MPL of 30 kg/m received the dose corresponding to a patient of 35 kg/m. The effective dose was estimated using the mean irradiated body length of 13.7 cm and the thorax conversion factor of 0.017 mSv/mGy/cm [16].
Validation
The optimized patient-specific CCTA protocol was implemented as a new routine clinical protocol. Next, to examine if the image noise was independent of patients’ size using the new protocol, the best explaining parameter P was correlated to the image noise for patients within the pre-specified range in groups A and B.
Statistics
All patient characteristics for groups A and B were presented as mean ± standard deviation (sd) and compared using the χ2 and unpaired t tests using Stata software (StataSE 12.0). To test if the regression coefficients of the σfit for each patient-specific parameter P differed significantly from zero, implying a significant correlation between σ and P or σnorm and P, t tests were performed. Coefficients of determination, R2, were determined for all fits and compared using the Hotelling–Williams test. Using the results of R2 and the Hotelling–Williams tests, the patient-specific parameter best explaining the σnorm was selected for the validation study.
The level of statistical significance was set to 0.05 for all statistical analyses.